Overview
The molecular basis of chronic myeloid leukemia (CML) is well understood. Central to CML pathology is the BCR-ABL chimeric gene, formed by a reciprocal translocation that brings the breakpoint cluster gene (BCR; OMIM accession number 151410) of chromosome 22 adjacent to the c-ABL oncogene 1 (ABL1; OMIM accession number 189980) on chromosome 9, producing the Philadelphia chromosome (Ph) (Figure 1) . The resulting BCR-ABL gene encodes a constitutively active tyrosine kinase, which is the fundamental cause of CML. 1 Tyrosine kinase inhibitors (TKIs) play a central role in the treatment of CML. Currently, 3 TKIs-imatinib, nilotinib, and dasatinib-are approved by the United States Food and Drug Administration for the treatment of CML. The goal of TKI therapy is to prolong survival by preventing transformation of the disease from the chronic phase to an advanced stage known as the blast phase, at which point median survival is 6 months. 1 CML treatment guidelines issued by the National Comprehensive Cancer Network (NCCN) and the European LeukemiaNet (ELN) represent an authoritative view on effective treatment and monitoring 2, 3 and emphasize that favorable outcomes rely on close monitoring of treatment response, with adjustments in therapy when patients' recovery levels do not meet treatment goals.
The categories of treatment response, in order of increasing sensitivity, are hematologic, cytogenetic, and molecular ( Figure 2) . 2, 4 The improved efficacy of TKIs relative to previous standards of care has necessitated the use of increasingly sensitive laboratory monitoring techniques; hence, molecular response has been the focus of much clinical research. Molecular response involves measurement of the transcript levels of BCR-ABL using quantitative real-time polymerase chain reaction (qRT-PCR). Quantitative assessment of BCR-ABL transcript levels by qRT-PCR has been validated as a surrogate marker of response to treatment 5 and has become a critical tool in the evaluation of responses to TKI therapy.
Importance of Assessing Molecular Response
The key response milestone, major molecular response (MMR), was defined in the pivotal International Randomized Study of Interferon and STI571 (IRIS) of imatinib versus interferon plus cytarabine as a 3-log or greater reduction in BCR-ABL transcripts from a standardized baseline. 6, 7 Data continue to be reported supporting the clinical importance and defining the prognostic value of achieving MMR. In the IRIS trial, patients who achieved MMR by 18 months and who did not progress to advanced disease during the subsequent 7 years demonstrated a 7-year event-free survival of 95%. 8 In the German CML Study IV, patients who had achieved MMR by 12 months had significantly prolonged progression-free survival and improved overall survival at 3 years. 9 Further, in the recently reported frontline studies of nilotinib and dasatinib, no patient who had achieved MMR displayed progression to advanced disease. 10, 11 Complete molecular response (CMR) is used to describe a response with BCR-ABL transcripts below the level of detection, 6 currently a 4.5-to 5-log reduction. The prognostic implications of CMR have not yet been established, to our knowledge; achievement of CMR has been reported only recently [12] [13] [14] as a clinical trial end point in studies of dasatinib and nilotinib in the frontline setting. Ongoing clinical trial data suggest that CMR may be of considerable value in identifying patients who may be candidates for discontinuation of TKI therapy. 15 Serial BCR-ABL monitoring provides a measure of the response to treatment, enabling rapid identification of patients with suboptimal response, loss of response, treatment failure (eg, due to primary or acquired resistance to current therapy), or lack of adherence to treatment and is used to guide clinical decisions for patient management. [16] [17] [18] The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines for Patients) and ELN recommendations encourage frequent monitoring of BCR-ABL transcript levels using qRT-PCR-that is, every 3 months until patients achieve complete cytogenetic response (NCCN Guidelines) or MMR (ELN recommendations). 2,3 Subsequent molecular monitoring is recommended every 3 or 6 months. 
Figure 1
The formation of the BCR-ABL chimeric gene (OMIM accession number 608232), the cause of chronic myeloid leukemia (CML).
A balanced translocation brings the Abelson (ABL) oncogene from chromosome 9 to chromosome 22, where the breakpoint cluster gene (BCR) resides, and results in formation of the BCR-ABL (OMIM accession number 608232) fusion gene. Levels of the BCR-ABL transcript provide a sensitive measure of treatment response. (Image courtesy of M. Wetzler, MD, FACP)
Figure 2
Treatment responses and BCR-ABL (OMIM accession number 608232) transcript levels. The 3 standard types of treatment response are shown herein, illustrating the decrease in the burden of leukemic cells as the patient transitions from complete hematologic response through complete cytogenetic response to major molecular response. Complete molecular response is achieved when transcripts are undetectable due to limitation of the sensitivity of the assay. Once a cytogenetic response has been achieved, further response can only be measured by molecular methods. 4 
Status of Molecular Monitoring
The frequency of molecular monitoring underscores the importance of accurate assays and clear laboratory reports. To be practical and to provide useful data, these reports must provide health care professionals with routine access to reliable qRT-PCR assays for serial measurements of BCR-ABL transcripts.
Two groups 19, 20 have noted the need for well-vetted housekeeping genes to use as internal controls for qRT-PCR. The Europe Against Cancer (EAC) program evaluated 14 genes and selected 3 of them-Abelson (ABL), beta-2-microglobulin (B2M), and betaglucuronidase (GUSB; OMIM accession number 611499)as being most suitable. 19 Wang and colleagues 20 examined 9 genes, selecting GUSB as the best internal control, used with the primer/probe set from Life Technologies Corporation (Carlsbad, CA). In contrast to the EAC group, Wang et al do not recommend ABL; they attribute differences in findings to the use of different primer sets in the 2 studies. 20 There is a clear need for standardization of BCR-ABL testing 21 because variations exist in the methods and materials used by different laboratories. Such variability may potentially be introduced at every stage of the qRT-PCR assay, from sample preparation and transportation through data analysis and report generation. 21 These factors may make it difficult to compare results between laboratories and even within the same laboratory, which impacts the validity of serial testing. Standardization of molecular monitoring is of great importance. Determination of MMR is dependent on the International Scale (IS) and, notably, the IS facilitates the "portability" of a patient's molecular response data, allowing comparison of BCR-ABL transcript levels between diagnostic laboratories (eg, if a patient has to relocate and transfers to a new physician).
Reporting Results from Molecular Monitoring
Differences in reporting results can limit the ability to compare results between laboratories, as well as between clinical studies and the results obtained in clinical practice. 21 BCR-ABL transcript levels are reported in several different ways ( Table 1) . 7, [22] [23] [24] The development of the IS for reporting BCR-ABL transcript levels enables all laboratories to report on a single scale. 7, 25 This scale is "anchored" to 2 predefined values: 100% on the IS corresponds to the baseline BCR-ABL level established in the IRIS trial, and a 3-log reduction is defined as 0.10% of the standardized baseline (ie, MMR). To convert locally determined BCR-ABL levels to the IS, a conversion factor specific to each local laboratory may be calculated using a set of certified samples after having verified BCR-ABL levels; these standard samples could potentially be plasmids, cell extracts, or lyophilized cells. Finally, the IS value is determined by BCR-ABL (local value) × conversion factor = BCR-ABL (IS). Ideally, internationally certified, commercially produced reference standards would be used as controls; this may, at least partially, replace the need for the method of aligning data mentioned earlier herein. The first such standards have been made available as a World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL by qRT-PCR. 26 The standards are freeze-dried and consist of a BCR-ABL-positive human erythroleukemia cell line (K562 cells) diluted in a human, BCR-ABL-negative leukemia cell line (HL60). The production of the first reference standard and its eventual increased availability offer hope of increased standardization between laboratories. 25, 26 Although there are benefits to the harmonization of methodologies, the use of the IS for reporting BCR-ABL transcript levels, as well as the use of standard reference materials, cannot address all potentially important sources of error in laboratory-developed tests. Use of standard materials and an IS conversion factor should help, but cannot ensure, quality control. 21 The efficacy of the IS is fundamentally limited by within-laboratory reproducibility. 21 Also, the conversion factor for each Overview laboratory cannot be considered a fixed value. Evidence suggests that it can be unstable, indicating the need for more frequent validation. 27 One approach to address these limitations is the development of instrumentation that provides fully automated nucleic acid purification, nested qRT-PCR, and data analysis. This approach reduces intraand interlaboratory variability and offers the potential for convenient cross-laboratory standardization. [28] [29] [30] 
Molecular Monitoring Report
The interface between the laboratory and the treating physician is the molecular pathology report. This report should have a clear layout, sufficient detail about the assay and its limitations, and technical and clinical conclusions. 31 Standardization of reports is recommended to ensure that all necessary information is presented. 31 This practice, together with the use of the IS, makes it far easier for the physician to compare reports from different laboratories. Moreover, a lack of standardization in a laboratory makes it more difficult to assess whether that laboratory is operating at an optimal quality assurance and quality control level compared with other laboratories.
Guidelines on what constitutes an optimal molecular pathology report have been published by the College of American Pathologists (CAP). 31, 32 The molecular pathologist provides the interpretation of the test results. This interpretation includes an analytical interpretation, in which the quality or quantity of the sample is assessed and a result is obtained, and a clinical interpretation, whereby the result is interpreted to reach a conclusion about its importance for the patient and his or her treatment. It should not be assumed that health care The limit of detection is an important component of the qRT-PCR BCR-ABL report because lack of detectability on a transcript is interpreted as achievement of CMR and has potential treatment implications. CAP recommendations note that any general comments providing background (eg, about test selection, limitations, and clinical significance) should be kept brief. 32 Other elements that should be included are reference gene(s) used for any ratio calculations, the conversion factor, and the result in IS format. Also, the patient's historical data are invaluable for demonstrating trends. Further, it is helpful to indicate for each reading whether it corresponds to MMR.
In light of these recommendations, it is informative to examine examples of molecular monitoring reports from testing laboratories (Figure 3) . Part A shows an example of a report for a patient with detectable BCR-ABL transcripts. Key parameters about the assay are provided (eg, interassay variability, limit of quantitation, and sensitivity), and the sample quality is described. The report clearly summarizes salient features without undue verbiage, highlighting that the patient's disease is currently in MMR, with historical data in the form of a table and graph that show whether MMR has been reached at each point. Values are reported in IS units for comparison with reports from other laboratories using the IS. This is a clear, easily interpreted report.
Panel B in Figure 3 shows a report of a patient without detectable BCR-ABL levels. This finding may mean that the patient is healthy and would not be diagnosed with CML. As stated in the report, if the patient has been treated for CML, it represents a dramatic 5-log or greater reduction in the BCR-ABL transcript level. The report provides key information to interpret the test, including scientific background, the typical result observed in untreated individuals with CML, analytical sensitivity, limitations of the test, and clinical implications if the result had shown a 3-log or greater reduction.
Molecular Monitoring: Present and Future
Currently, most molecular pathology diagnostics are carried out using assays tailored to a particular laboratory (known as laboratory-developed tests). Despite the commercial availability of reagents and kits to facilitate the process ( Table 2) , variation and error may still occur. 21 Hence, the unmet need for an accurate, automated, standardized, and reproducible method to perform BCR-ABL assays has led to the development of the GeneXpert System (Cepheid, Sunnyvale, CA). 28, 29 This instrument automates all steps in the process of measuring BCR-ABL transcript levels directly from a patient sample, producing a result that is converted to the IS and is complete in approximately 2 hours. However, there are several potential limitations of the automated Cepheid system, such as its inflexibility in choice of the housekeeping gene, cost, and low throughput. Also, this instrumentation does not support the use of other laboratory-developed tests. As use of molecular methods becomes a more standard part of clinical practice, development of rapid, accurate, and reproducible assays for molecular markers will continue to be refined.
Further, as technology evolves, the ability to detect BCR-ABL transcripts below the current limit of quantification improves. More sensitive methodologies are in development, such as digital PCR; in the future, these methodologies may provide a definition of CMR that more closely reflects complete eradication of the CML clone. 33 Therefore, with the potential for discontinuation of treatment on the horizon, 15 the identification of patients who exhibit CMR becomes increasingly important. With continuing clinical trials and drug development for the treatment of CML, as well as the ability to detect smaller quantities of BCR-ABL transcripts in the molecular laboratory, a cure may be possible for patients with CML.
Conclusions
Molecular monitoring of BCR-ABL transcript levels through qRT-PCR is central to modern monitoring of patients with CML, providing important clinical information for monitoring patient response to therapy with TKIs and for determining whether a change in treatment is warranted. Conventional methods of qRT-PCR are complex to perform, involve
Overview Measurement accuracy and interlaboratory comparisons can be improved through the adoption of harmonized international guidelines and the IS. Also, there is mounting evidence that achievement of CMR may allow some patients to discontinue TKI therapy. The improvements in treatment efficacy and in molecular monitoring are exciting in that curative intent may be possible with TKI therapy but challenging because the onus is on pathologists to ensure accurate reports of molecular response based on validated, standardized methodology. These reports will directly influence clinical decision-making for patient care and will signal whether TKI therapy needs to be adjusted or potentially discontinued. LM 
